Oritavancin (diphosphate)


CAS No. : 192564-14-0

(Synonyms: LY333328 diphosphate)

192564-14-0
Price and Availability of CAS No. : 192564-14-0
Size Price Stock
2mg $50 In-stock
5mg $85 In-stock
10mg $135 In-stock
50mg $450 In-stock
100mg $720 In-stock
200 mg Get quote
500 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-B1831A
M.Wt: 1989.09
Formula: C86H103Cl3N10O34P2
Purity: >98 %
Solubility: DMSO : 41.67 mg/mL (ultrasonic);H2O : 50 mg/mL (ultrasonic)
Introduction of 192564-14-0 :

Oritavancin diphosphate (LY333328 diphosphate), a semisynthetic derivative of Vancomycin (HY-B0671), is an orally active glycopeptide antibiotic with bactericidal activity against gram-positive organisms. Oritavancin diphosphate shows antibacterial effect against B. anthracis, such as Ames strain with a MIC value of 0.015 g/mL. Oritavancin diphosphate inhibits cell wall synthesis and disrupts the membrane potential. Oritavancin diphosphate inhibits ArlS kinase activity thereby interfering the signal transduction. Oritavancin diphosphate enters cells by adsorptive endocytosis, which drives it to lysosomes, where it exerts antibiotic activity[1][2][3][4][5]. In Vitro: Oritavancin diphosphate (25 μM, 30 min) dose-dependently inhibits the kinase activity of ArlS (3 μg) by 98% with an IC50 value of 5.47 μΜ in vitro[1].
Oritavancin diphosphate (0.7 μM, 42 h) decreases spx expression in the USA300-Pspx strain[1].
Oritavancin diphosphate (3.1 μM, 24 h) disrupts mature MRSA biofilms and facilitates bactericidal activity of oritavancin diphosphate and Oxacillin (HY-B0925A) against embedded S. aureus cells[1].
Oritavancin diphosphate’ (0-80 μg/mL, 2 h) incubation with increasing extracellular concentrations and the uptake by cells proceed in a cooperative manner in J774 macrophages[2].
Oritavancin diphosphate (25 mg/L, 24 h) exerts a marked bactericidal effect against intracellular S. aureus[2].

Oritavancin diphosphate accumulation by different cell types[2]

(The cells were incubated for 2 h at 37°C with 25 mg of the drug per liter in a medium containing 10% FCS)[2]
Cell type Accumulation ratio (no. of determinations)
J774 mouse macrophages 66.4±11.8 (12)
THP-1 human monocytes 84.3±7.0 (9)
Rat embryo fibroblasts 72.4±9.4 (6)
LLC-PK1 pig kidney proximal tubular cells 37.8±6.4 (3)
Caco-2 human colorectal cells. 13.8±0.4 (3)
In Vivo: Oritavancin diphosphate (i.p. for 1 and 3 mg/kg or i.v. for 15 and 50 mg/kg, every 48 h for 14 days or a single dose for 30 days) provides significant protection in the mouse inhalation anthrax model[3].

Your information is safe with us.